27513632|t|miR‑221 targets HMGA2 to inhibit bleomycin ‑induced pulmonary fibrosis by regulating TGF‑β1 / Smad3 -induced EMT
27513632|a|MicroRNA (miR)-221 plays an essential role in the epithelial-mesenchymal transition (EMT). High mobility group AT-hook 2 (HMGA2), is a key regulator of EMT. However, the role of miR‑221 in pulmonary fibrosis, and the association between miR‑221 and HMGA2 remain largely unknown. For this purpose, we examined the expression of miR‑221 and HMGA2 in human idiopathic pulmonary fibrosis (IPF) tissues and pulmonary cells, namely the adenocarcinoma A549 and human bronchial epithelium (HBE) cell lines, and found that the expression of miR‑221 was inhibited in both tissues and cells whereas high mRNA and protein expression of HMGA2 was observed. Additionally, transforming growth factor‑β1 (TGF‑β1) induced the EMT, characterized by the upregulated expression of the mesenchymal markers, namely N‑cadherin, vimentin, α‑smooth muscle actin, collagen I and collagen III, and the downregulated expression of the epithelial marker E-cadherin in A549 and HBE cells. We then performed transfection with miR‑221 mimics, and found that the expression of phosphorylated - Smad3 in miR‑221 ‑ overexpressing cells was significantly downregulated, compared with that in the TGF‑β1 -treated cells without transfection. Furthermore, the overexpression of miR‑221 decreased the expression of HMGA2, suppressed the EMT, and inhibited the proliferation of A549 and HBE cells. HMGA2 was directly targeted by miR‑221 which was confirmed by the dual-luciferase reporter gene assay. Finally, a mouse model of bleomycin (BLM)‑induced pulmonary fibrosis was used to confirm the effect of miR‑221 on EMT. Hematoxylin and eosin staining showed that BLM induced thicker alveolar walls and more collagen deposition, whereas miR‑221 treatment reduced lung fibrosis and the tissues exhibited thinner alveolar walls and normal lung alveoli. Furthermore, the EMT process was suppressed following miR‑221 injection. Taken together, these findings sugest that miR‑221 targets HMGA2 to inhibit BLM ‑induced pulmonary fibrosis through the TGF‑β1 / Smad3 signaling pathway.
27513632	0	7	miR‑221	T114	C2003459
27513632	16	21	HMGA2	T116,T123	C0122111
27513632	25	32	inhibit	T052	C3463820
27513632	33	42	bleomycin	T116,T195	C0005740
27513632	52	70	pulmonary fibrosis	T047	C0034069
27513632	85	91	TGF‑β1	T116,T121,T123	C1704256
27513632	94	99	Smad3	T116,T123	C0529119
27513632	109	112	EMT	T043	C1523298
27513632	113	131	MicroRNA (miR)-221	T114	C2003459
27513632	163	196	epithelial-mesenchymal transition	T043	C1523298
27513632	198	201	EMT	T043	C1523298
27513632	204	233	High mobility group AT-hook 2	T116,T123	C0122111
27513632	235	240	HMGA2	T116,T123	C0122111
27513632	252	261	regulator	T077	C1704735
27513632	265	268	EMT	T043	C1523298
27513632	291	298	miR‑221	T114	C2003459
27513632	302	320	pulmonary fibrosis	T047	C0034069
27513632	330	341	association	T080	C0439849
27513632	350	357	miR‑221	T114	C2003459
27513632	362	367	HMGA2	T116,T123	C0122111
27513632	426	436	expression	T045	C0017262
27513632	440	447	miR‑221	T028	C1537859
27513632	452	457	HMGA2	T116,T123	C0122111
27513632	461	466	human	T016	C0086418
27513632	467	496	idiopathic pulmonary fibrosis	T047	C1800706
27513632	498	501	IPF	T047	C1800706
27513632	503	510	tissues	T024	C0040300
27513632	515	524	pulmonary	T023	C0024109
27513632	525	530	cells	T025	C0007634
27513632	543	557	adenocarcinoma	T191	C0001418
27513632	558	562	A549	T025	C4277577
27513632	567	572	human	T016	C0086418
27513632	573	593	bronchial epithelium	T023	C0599333
27513632	595	598	HBE	T023	C0599333
27513632	600	610	cell lines	T025	C0682523
27513632	631	641	expression	T045	C0017262
27513632	645	652	miR‑221	T028	C1537859
27513632	657	666	inhibited	T052	C3463820
27513632	675	682	tissues	T024	C0040300
27513632	687	692	cells	T025	C0007634
27513632	706	710	mRNA	T114,T123	C0035696
27513632	715	733	protein expression	T045	C1171362
27513632	737	742	HMGA2	T116,T123	C0122111
27513632	771	800	transforming growth factor‑β1	T116,T121,T123	C1704256
27513632	802	808	TGF‑β1	T116,T121,T123	C1704256
27513632	822	825	EMT	T043	C1523298
27513632	848	859	upregulated	T044	C0041904
27513632	860	870	expression	T059	C0600223
27513632	878	897	mesenchymal markers	T045	C0017393
27513632	906	916	N‑cadherin	T116,T123	C0027215
27513632	918	926	vimentin	T116,T123	C0042666
27513632	928	949	α‑smooth muscle actin	T116,T123	C2716282
27513632	951	961	collagen I	T116,T123	C0041455
27513632	966	978	collagen III	T116,T123	C0009332
27513632	988	1001	downregulated	T044	C0013081
27513632	1002	1012	expression	T059	C0600223
27513632	1020	1037	epithelial marker	T045	C0017393
27513632	1038	1048	E-cadherin	T116,T123	C0042172
27513632	1052	1056	A549	T025	C4277577
27513632	1061	1070	HBE cells	T025	C0014597
27513632	1090	1102	transfection	T045	C0314641
27513632	1108	1115	miR‑221	T114	C2003459
27513632	1143	1153	expression	T045	C1171362
27513632	1157	1171	phosphorylated	T044	C1158886
27513632	1174	1179	Smad3	T116,T123	C0529119
27513632	1183	1190	miR‑221	T028	C1537859
27513632	1193	1207	overexpressing	T045	C0017262
27513632	1208	1213	cells	T025	C0007634
27513632	1232	1245	downregulated	T044	C0013081
27513632	1273	1279	TGF‑β1	T116,T121,T123	C1704256
27513632	1289	1294	cells	T025	C0007634
27513632	1303	1315	transfection	T045	C0314641
27513632	1334	1348	overexpression	T045	C0017262
27513632	1352	1359	miR‑221	T028	C1537859
27513632	1374	1384	expression	T045	C1171362
27513632	1388	1393	HMGA2	T116,T123	C0122111
27513632	1410	1413	EMT	T043	C1523298
27513632	1419	1428	inhibited	T052	C3463820
27513632	1433	1446	proliferation	T043	C0596290
27513632	1450	1454	A549	T025	C4277577
27513632	1459	1468	HBE cells	T025	C0014597
27513632	1470	1475	HMGA2	T116,T123	C0122111
27513632	1501	1508	miR‑221	T114	C2003459
27513632	1561	1571	gene assay	T059	C0022885
27513632	1584	1595	mouse model	T050	C2986594
27513632	1599	1608	bleomycin	T116,T195	C0005740
27513632	1610	1613	BLM	T116,T195	C0005740
27513632	1623	1641	pulmonary fibrosis	T047	C0034069
27513632	1676	1683	miR‑221	T114	C2744274
27513632	1687	1690	EMT	T043	C1523298
27513632	1692	1722	Hematoxylin and eosin staining	T059	C0523207
27513632	1735	1738	BLM	T116,T195	C0005740
27513632	1755	1769	alveolar walls	T023	C0225695
27513632	1779	1787	collagen	T116	C0009325
27513632	1788	1798	deposition	T169	C0333562
27513632	1808	1815	miR‑221	T114	C2744274
27513632	1816	1825	treatment	T169	C1522326
27513632	1834	1847	lung fibrosis	T047	C0034069
27513632	1856	1863	tissues	T024	C0040300
27513632	1882	1896	alveolar walls	T023	C0225695
27513632	1908	1920	lung alveoli	T023	C0034051
27513632	1939	1950	EMT process	T043	C1523298
27513632	1976	1983	miR‑221	T114	C2744274
27513632	2038	2045	miR‑221	T114	C2003459
27513632	2054	2059	HMGA2	T116,T123	C0122111
27513632	2063	2070	inhibit	T052	C3463820
27513632	2071	2074	BLM	T116,T195	C0005740
27513632	2084	2102	pulmonary fibrosis	T047	C0034069
27513632	2115	2121	TGF‑β1	T116,T121,T123	C1704256
27513632	2124	2129	Smad3	T116,T123	C1566798
27513632	2130	2147	signaling pathway	T044	C0037080